Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate after discussions with the U.S. Food and Drug Administration. The company said it would resubmit the application later this year with vaccine efficacy data from a late-stage trial of its experimental seasonal influenza vaccine,

The Trump administration shared the outlines of how it plans to push drug companies to lower their prices in the U.S.

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from yesterday.

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot,

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they are safe and effective.

Moderna stock toppled Wednesday after the company withdrew its application for a combination Covid and flu vaccine.

Shares of Moderna surged to lead S&P 500 gainers in early afternoon trading Tuesday, hours after the Food and Drug Administration (FDA) issued new guidance for COVID-19 vaccine boosters for healthy Americans under age 65.

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.